Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Specific human granulocyte-macrophage colony-stimulating factor antagonists

T R Hercus1, C J Bagley, B Cambareri

  • 1Division of Human Immunology, Hanson Centre for Cancer Research, Institute of Medical and Veterinary Science, Adelaide, South Australia.

Proceedings of the National Academy of Sciences of the United States of America
|June 21, 1994
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CIB1 contributes to oncogenic signalling by Ras via modulating the subcellular localisation of sphingosine kinase 1.

Oncogene·2016
Same author

TGF-α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy.

Leukemia·2016
Same author

Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC.

Leukemia·2014
Same author

Molecular targets of FTY720 (fingolimod).

Current molecular medicine·2012
Same author

Neurodevelopmental and neuropsychiatric behaviour defects arise from 14-3-3ζ deficiency.

Molecular psychiatry·2011
Same author

Cytokine receptor signaling activates an IKK-dependent phosphorylation of PUMA to prevent cell death.

Cell death and differentiation·2011

Human granulocyte-macrophage colony-stimulating factor (GM-CSF) mutants E21R and E21K bind weakly but block GM-CSF activity. These GM-CSF antagonists show potential for treating inflammatory diseases and leukemias.

Area of Science:

  • Biochemistry
  • Immunology
  • Molecular Biology

Background:

  • Human granulocyte-macrophage colony-stimulating factor (GM-CSF) is a key regulator of myeloid cell function.
  • Residue 21 in GM-CSF's first helix is crucial for receptor binding and biological activity.

Purpose of the Study:

  • To investigate the role of residue 21 in GM-CSF receptor binding and activity.
  • To generate and characterize GM-CSF analogues with mutations at residue 21.
  • To explore the potential of these analogues as antagonists for therapeutic applications.

Main Methods:

  • Site-directed mutagenesis of GM-CSF at residue 21.
  • Expression and purification of GM-CSF analogues in Escherichia coli.
  • Binding assays with GM-CSF receptor components.

Related Experiment Videos

  • Functional assays measuring cell proliferation and neutrophil superoxide production.

    • Main Results:

    • Mutants E21A, E21Q, E21F, E21H, E21R, and E21K bound the GM-CSF receptor alpha chain but lost high-affinity binding to the receptor complex.
    • Charge reversal mutants E21R and E21K were devoid of agonistic activity.
    • E21R and E21K specifically antagonized GM-CSF-mediated proliferation and neutrophil activation.
    • These antagonists were effective against both glycosylated and nonglycosylated wild-type GM-CSF.

    Conclusions:

    • Low-affinity GM-CSF binding can be uncoupled from receptor activation.
    • GM-CSF mutants E21R and E21K function as specific antagonists.
    • These antagonists hold potential for managing inflammatory diseases and certain leukemias involving pathogenic GM-CSF activity.